These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1232 related articles for article (PubMed ID: 18343274)

  • 21. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
    Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
    Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients.
    Schumock GT; Andress DL; Marx SE; Sterz R; Joyce AT; Kalantar-Zadeh K
    Nephron Clin Pract; 2009; 113(1):c54-61. PubMed ID: 19590235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
    Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
    Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.
    Faught RE; Weiner JR; Guérin A; Cunnington MC; Duh MS
    Epilepsia; 2009 Mar; 50(3):501-9. PubMed ID: 19183224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges.
    Keating KN; Friedman HS; Perfetto EM
    Curr Med Res Opin; 2006 Feb; 22(2):327-33. PubMed ID: 16466604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project.
    Bratzler DW; Ma A; Nsa W
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S193-201. PubMed ID: 18986289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia.
    Wasserfallen JB; Erard V; Cometta A; Calandra T; Lamy O
    Eur Respir J; 2004 Oct; 24(4):644-8. PubMed ID: 15459145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes and costs of patients with persistent asthma treated with beclomethasone dipropionate hydrofluoroalkane or fluticasone propionate.
    Lage MJ; Gross GN; Brewster C; Spalitto A
    Adv Ther; 2009 Aug; 26(8):762-75. PubMed ID: 19669630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
    Segreti J; House HR; Siegel RE
    Am J Med; 2005 Jul; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of community-acquired pneumonia by trained family general practitioners.
    Potena A; Simoni M; Cellini M; Cartabellotta A; Ballerin L; Piattella M; Putinati S
    Int J Tuberc Lung Dis; 2008 Jan; 12(1):19-25. PubMed ID: 18173872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and cost-effectiveness of antibiotic treatments for community acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB).
    Lavoie F; Blais L; Castilloux AM; Scalera A; LeLorier J
    Can J Clin Pharmacol; 2005; 12(2):e212-7. PubMed ID: 15998960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
    Tennenberg AM; Davis NB; Wu SC; Kahn J
    Curr Med Res Opin; 2006 May; 22(5):843-50. PubMed ID: 16709306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
    Martin M; Moore L; Quilici S; Decramer M; Simoens S
    Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy.
    Mykietiuk A; Carratalà J; Fernández-Sabé N; Dorca J; Verdaguer R; Manresa F; Gudiol F
    Clin Infect Dis; 2005 Mar; 40(6):794-9. PubMed ID: 15736010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.
    Dunbar LM; Khashab MM; Kahn JB; Zadeikis N; Xiang JX; Tennenberg AM
    Curr Med Res Opin; 2004 Apr; 20(4):555-63. PubMed ID: 15119993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.